Wednesday, July 8, 2026
🇺🇸 FDA

biotech · Recurrent Plasma Cell Myeloma · Anal Cancer Metastatic · ONCY

Oncolytics Biotech

ONCOLYTICS BIOTECH INC

Oncolytics Biotech patent portfolio — 66 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

Website Investor relations
4350 Executive Dr, 325, San Diego, California 92121, US HQ
1998 Founded
46 Employees
Public company Type
ONCY · NYSE Ticker
Company details
Status
Public
HQ
4350 Executive Dr, 325, San Diego, California 92121, US
Founded
1998
Employees
46
Programs
23
Drugs
14
Patents
66
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Patents

Oncolytics Biotech patents

66 pharmaceutical patents indexed for Oncolytics Biotech. 9 expire within 24 months.

Oncolytics Biotech has 66 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 9 expire within 24 months — use filters for patent-cliff planning.

All patents Expiring ≤12 months Expiring ≤24 months

66 patents

Patent portfolio

Page 1 of 2

  1. US 11542526

    Oncolytic adenoviral vector and methods of use

    Expires Mon Dec 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11246930

    Reoviruses having modified sequences

    Expires Mon Feb 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10596260

    Reoviruses having modified sequences

    Expires Mon Mar 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10167452

    Viral purification methods

    Expires Mon Dec 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10039827

    Reoviruses having modified sequences

    Expires Mon Aug 02 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 9610309

    Liquid viral formulations

    Expires Mon Mar 30 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 9610352

    Lyophilized viral formulations

    Expires Mon Mar 30 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 9365823

    Virus clearance of neoplastic cells from mixed cellular compositions

    Expires Mon Jun 09 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 9044498

    Lyophilized viral formulations

    Expires Mon May 28 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 9045728

    Liquid viral formulations

    Expires Mon May 28 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 8709443

    Reovirus for the treatment of cellular proliferative disorders

    Expires Mon Apr 24 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 8691241

    Reoviruses having modified sequences

    Expires Mon Apr 03 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 8685734

    Viral purification methods

    Expires Mon Mar 27 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 8658158

    Sensitization of chemotherapeutic agent resistant neoplastic cells with a virus

    Expires Mon Feb 20 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 8512712

    Reovirus clearance of ras-mediated neoplastic cells from mixed cellular compositions

    Expires Mon Aug 15 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 8491884

    Virus clearance of neoplastic cells from mixed cellular compositions

    Expires Mon Jul 18 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 8491886

    Viruses for the treatment of cellular proliferative disorders

    Expires Mon Jul 18 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 8470312

    Abrogating proinflammatory cytokine production during oncolytic reovirus therapy

    Expires Mon Jun 20 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 8293267

    Method for preparing an antimicrobial cotton of cellulose matrix having chemically and/or physically bonded silver and antimicrobial cotton prepared therefrom

    Expires Mon Oct 18 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 8147845

    Reovirus clearance of ras-mediated neoplastic cells from mixed cellular compositions

    Expires Mon Mar 29 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 8080241

    Viruses for the treatment of cellular proliferative disorders

    Expires Mon Dec 15 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 8071087

    Reovirus for the treatment of cellular proliferative disorders

    Expires Mon Dec 01 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 8066985

    Reovirus for the treatment of cellular proliferative disorders

    Expires Mon Nov 24 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 7964187

    Sensitization of chemotherapeutic agent resistant neoplastic cells with a virus

    Expires Mon Jun 16 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 7964186

    Viruses for the treatment of cellular proliferative disorders

    Expires Mon Jun 16 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 7901921

    Viral purification methods

    Expires Mon Mar 03 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 7815914

    Methods for the treatment of cellular proliferative disorders

    Expires Mon Oct 14 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 7803385

    Reoviruses having modified sequences

    Expires Mon Sep 23 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 7799329

    Viruses for the treatment of cellular proliferative disorders

    Expires Mon Sep 16 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 7763252

    Methods for the treatment of cellular proliferative disorders

    Expires Mon Jul 22 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 7731951

    Viruses for the treatment of cellular proliferative disorders

    Expires Mon Jun 03 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 7727534

    Reovirus clearance of ras-mediated neoplastic cells from mixed cellular compositions

    Expires Mon May 27 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 7708987

    Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders

    Expires Mon Apr 29 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 7608257

    Sensitization of chemotherapeutic agent resistant neoplastic cells with a virus

    Expires Mon Oct 22 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 7582289

    Viruses for the treatment of cellular proliferative disorders

    Expires Mon Aug 27 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 7476382

    Reovirus for the treatment of neoplasia

    Expires Mon Jan 08 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 7452723

    Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders

    Expires Mon Nov 13 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 7431932

    Reovirus clearance of ras-mediated neoplastic cells from mixed cellular compositions

    Expires Mon Oct 02 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 7429485

    Method of producing infectious reovirus

    Expires Mon Sep 25 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 7374752

    Reovirus for the treatment of cellular proliferative disorders

    Expires Mon May 15 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 7344711

    Use of adenoviruses mutated in the VA genes for cancer treatment

    Expires Mon Mar 13 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 7300650

    Reovirus for the treatment of neoplasia

    Expires Mon Nov 22 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 7264798

    Sensitization of chemotherapeutic agent resistant neoplastic cells with a virus

    Expires Mon Aug 30 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 7252817

    Viruses for the treatment of cellular proliferative disorders

    Expires Mon Aug 02 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 7223585

    Viral purification methods

    Expires Mon May 24 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 7198783

    Sensitization of neoplastic cells to radiation therapy with reovirus

    Expires Mon Mar 29 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 7186542

    Method of extracting virus from cell culture

    Expires Mon Mar 01 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 7163678

    Reovirus for the treatment of ral-mediated cellular proliferative disorders

    Expires Mon Jan 11 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Oncolytics Biotech have?

66 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Oncolytics Biotech patents expire?

9 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.